The Role of Multimodality Imaging in Monitoring Disease Activity and Therapeutic Response to Tocilizumab in Giant Cell Arteritis

Table 2

Patient imaging findings before and after tocilizumab treatment.

Pt	Gender	Age	PET (Meller scale) at baseline	PET (Meller scale) at follow-up	MRA at baseline	MRA at follow-up	CTA at baseline	CTA at follow-up	CDUS IMT at baseline (mm)	CDUS IMT at follow-up (mm)
1	F	65	—	—	—	—	—	—	0.7 (TA)	0.4 (TA)
2	F	64	III	0	—	—	—	—		0.7
3	F	70	III	0	Right ICA occlusion; CCA, left SA, and VA thickening	ICA partially recovered; other arteries fully resolved	—	—	1.5 (CCA)	0.7 (CCA)
4	F	74	III	0	—	—	—	—	—	—
5	F	78	—	—	—	—	—	—	0.6 (TA)	0.2 (TA)
6	F	56	III	0	—	—	Aortic wall thickening	Negative	—	—
7	F	77	III	I	—	—	Aortic wall thickening	Negative	—	—
8	M	60	III	I	—	—	Aortic wall thickening	Negative	—	—
9	F	85	—	—	—	—	—	—	0.7 (TA)	0.3 (TA)
10	M	77	III	0	ICA enhancement	Negative	—	—	1.2 (CCA)	0.7 (CCA)
11	M	65	III	I	—	—	—	—	1.4 (AxA)	0.8 (AxA)

AxA: axillary artery; CCA: common carotid artery; CDUS: color Doppler ultrasonography; CTA: computed tomography angiography; ICA: internal carotid artery; IMT: intima-media thickness; MRA: magnetic resonance angiography; PET: positron emission tomography; SA: subclavian artery; SUV: standardized uptake value; TA: temporal artery; VA: vertebral artery.